Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults

• المؤلفون الرئيسيون: Foca M., Yogev R., Wiznia A., Hazra R., Jean-Philippe P., Graham B., Britto P., Carey V., King J., Acosta E., Cressey T.
• التنسيق: دورية
• منشور في: 2017
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84969217101&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/41631

© 2016 Wolters Kluwer Health, Inc. Background: Rilpivirine (RPV), a recently developed, once daily human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor, is not currently approved for pediatric patients, but is sometimes prescribed for adolescents with multiple treatment failur...